Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi‐institutional retrospective study

Risk‐scoring systems for colorectal liver metastasis (CRLM) after hepatectomy allow prognoses to be predicted preoperatively. We investigated the clinical outcomes of neoadjuvant chemotherapy for resectable CRLM according to patient risk status, aiming to determine the subgroup of patients who could benefit from neoadjuvant chemotherapy.

[1]  A. Lièvre,et al.  Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. , 2022, Critical reviews in oncology/hematology.

[2]  M. Unno,et al.  A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study , 2022, Langenbeck's Archives of Surgery.

[3]  M. Ychou,et al.  Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial , 2022, British Journal of Cancer.

[4]  M. Morita,et al.  Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis , 2021, Surgery Today.

[5]  H. Kuwano,et al.  Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases , 2021, International Journal of Clinical Oncology.

[6]  H. Ohdan,et al.  Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis , 2020, World Journal of Surgical Oncology.

[7]  大腸癌研究会.  Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d English Edition [Secondary Publication] , 2019, Journal of the anus, rectum and colon.

[8]  E. Oki,et al.  Recent advances in treatment for colorectal liver metastasis , 2018, Annals of gastroenterological surgery.

[9]  Shuji Takiguchi,et al.  Gastroenterological surgery in Japan: The past, the present and the future , 2017, Annals of gastroenterological surgery.

[10]  D. Sabanathan,et al.  Use of Neoadjuvant Chemotherapy Plus Molecular Targeted Therapy in Colorectal Liver Metastases: A Systematic Review and Meta-analysis. , 2016, Clinical colorectal cancer.

[11]  P. Bachellier,et al.  Factors influencing recurrence following initial hepatectomy for colorectal liver metastases , 2016, The British journal of surgery.

[12]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Nagatsu,et al.  Long-Term Outcomes of Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastases , 2016, Annals of Surgical Oncology.

[14]  M. Kudo,et al.  General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan , 2015, Digestive Diseases.

[15]  H. Katayama,et al.  Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria , 2015, Surgery Today.

[16]  C. Verhoef,et al.  The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  C. Dejong,et al.  Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial , 2015, BMC Cancer.

[18]  T. Utsunomiya,et al.  Evaluation and management of hepatic injury induced by oxaliplatin‐based chemotherapy in patients with hepatic resection for colorectal liver metastasis , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[19]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[20]  R. Parks,et al.  Surgery for Colorectal Liver Metastases , 2013, Digestive Surgery.

[21]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[22]  M. Makuuchi,et al.  Liver Resection for Multiple Colorectal Liver Metastases with Surgery Up-front Approach: Bi-institutional Analysis of 736 Consecutive Cases , 2012, World Journal of Surgery.

[23]  Abhi Shelat,et al.  One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.

[24]  R. Parks,et al.  Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983) , 2012, Annals of surgery.

[25]  G. Honda,et al.  A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery , 2012, Journal of hepato-biliary-pancreatic sciences.

[26]  I. Pedley,et al.  Systemic chemotherapy and its implications for resection of colorectal liver metastasis. , 2011, Surgical oncology.

[27]  D. Sargent,et al.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Thomas Gruenberger,et al.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial , 2008, The Lancet.

[29]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[30]  B. Nordlinger,et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.

[31]  H. Yasunaga.  Introduction to Applied Statistics—Chapter 1 Propensity Score Analysis , 2020, Annals of Clinical Epidemiology.

[32]  K. Hatakeyama,et al.  Histologic evaluation of intrahepatic micrometastases in patients treated with or without neoadjuvant chemotherapy for colorectal carcinoma liver metastasis. , 2012, International journal of clinical and experimental pathology.

[33]  T. Eberlein.  Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy , 2011 .

[34]  P. D. L. David L. Morris MD,et al.  Systematic Review of Randomized and Nonrandomized Trials of the Clinical Response and Outcomes of Neoadjuvant Systemic Chemotherapy for Resectable Colorectal Liver Metastases , 2009, Annals of Surgical Oncology.